Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias

• Main Authors: Cappellini, M.D., Porter, J., El-Beshlawy, A., Li, C.K., Seymour, J.F., Elalfy, M., Gattermann, N., Giraudier, S., Lee, J.W., Chan, L.L., Lin, K.H., Rose, C., Taher, A., Thein, S.L., Viprakasit, V., Habr, D., Domokos, G., Roubert, B., Kattamis, A., Investigators, EPIC Study
• Format: Article
• Published: 2010
• Subjects: R Medicine
• Online Access: http://eprints.um.edu.my/14887/

Background Following a clinical evaluation of deferasirox (Exjade (R)) it was concluded that, in addition to baseline body iron burden, ongoing transfusional iron intake should be considered when selecting doses. The 1-year EPIC study, the largest ever investigation conducted for an iron chelator, i...